key: cord-0937651-w0bbjz3b
authors: Li, Jie; Huang, Daniel Q.; Zou, Biyao; Yang, Hongli; Hui, Wan Zi; Rui, Fajuan; Yee, Natasha Tang Sook; Liu, Chuanli; Nerurkar, Sanjna Nilesh; Kai, Justin Chua Ying; Teng, Margaret Li Peng; Li, Xiaohe; Zeng, Hua; Borghi, John A.; Henry, Linda; Cheung, Ramsey; Nguyen, Mindie H.
title: Epidemiology of COVID‐19: A Systematic Review and Meta‐analysis of Clinical Characteristics, Risk factors and Outcomes
date: 2020-08-13
journal: J Med Virol
DOI: 10.1002/jmv.26424
sha: 8cc2b01c974c66dc786dffbe7f4bf341392a995d
doc_id: 937651
cord_uid: w0bbjz3b

BACKGROUND: COVID‐19 has become a pandemic, but its reported characteristics and outcomes vary greatly amongst studies. OBJECTIVES: We determined pooled estimates for clinical characteristics and outcomes in COVID‐19 patients including subgroups by disease severity (based on WHO Interim Guidance Report or IDSA/ATS criteria) and by country/region. METHODS: We searched Pubmed, Embase, Scopus, Cochrane, Chinese Medical Journal, and preprint databases from January 1, 2020 to April 6, 2020. Studies of laboratory confirmed COVID‐19 patients with relevant data were included. Two reviewers independently performed study selection and data extraction. RESULTS: From 6,007 articles, 212 studies from 11 countries/regions involving 281,461 individuals were analyzed. Overall, mean age was 46.7 years, 51.8% were male, 22.9% had severe disease, and mortality was 5.6%. Underlying immunosuppression, diabetes, and malignancy were most strongly associated with severe COVID‐19 (coefficient=53.9, 23.4, 23.4, respectively, all p<0.0007), while older age, male gender, diabetes, and hypertension were also associated with higher mortality (coefficient=0.05 per year, 5.1, 8.2, 6.99, respectively, p=0.006 to 0.0002). Gastrointestinal (nausea, vomiting, abdominal pain) and respiratory symptoms (shortness of breath, chest pain) were associated with severe COVID‐19, while pneumonia and end organ failure were associated with mortality. CONCLUSION: COVID‐19 is associated with a severe disease course in about 23% and mortality in about 6% of infected persons. Individuals with comorbidities and clinical features associated with severity should be monitored closely, and preventive efforts should especially target those with diabetes, malignancy and immunosuppression. This article is protected by copyright. All rights reserved.

were included only in subgroup analyses (Figure 1) . Some studies provided data for more than one analysis, hence the sum added up to be greater than 212.

The quality assessment for each paper is included in Supplemental Table 1 . The average NOS score was 7, with 122 studies being of high quality, 90 of medium quality, and none of low quality.

The majority of study patients came from the USA (n=223,862; 79.5%) followed by Mainland China (n=24,605; 8.7%), Italy (n=24,105; 8.6%), and South Korea (n=7,848; 2.8%). The individual study sample sizes ranged from 1 to 149,082 (Supplemental Table 1 ).

The pooled mean age in the overall cohort was 46.7 years (95% CI 42.8-50.5) using data from 88 studies (n=8,908) ( Table 1) and was similar between patients from Mainland China and outside Mainland China (p=0.1) (Supplemental Table   2A ), and within Mainland China between those from Hubei versus outside Hubei (p=0.08) (Supplemental Table 2B ). Tables 2A and 2B) .

Of the 212 studies, 190 (89.6%) studies used polymerase chain reaction (PCR) alone to diagnose COVID-19, one study (0.5%) used a serum antibody test alone, nine (4.3%) studies used a combination of chest CT and PCR tests, one study (0.5%) used a combination of chest CT and antibody tests, and one study (0.5%) used a combination of PCR, chest CT and antibody tests. The remaining 10 (4.7%) studies did not specify how COVID-19 was diagnosed. Studies from all countries apart from Mainland China relied on PCR alone to diagnose COVID-19.

The pooled mean incubation period in the overall cohort was 5.3 days (95% CI 4.5-6.0) (seven studies, 746 patients, Table 1 ). The incubation period was shorter in studies outside Mainland China (4.0 days, 95% CI 3.0-5.1) versus 6.0 days (95% CI 4.7-7.3) in Mainland China (p=0.02) (Supplemental Table 2A ).

However, there was only one study that provided data for incubation period outside of Mainland China. Within Mainland China, there was no difference in the incubation period when stratified by Hubei versus outside Hubei (p=0.4) (Supplemental Table 2B ).

This article is protected by copyright. All rights reserved.

A total of 161 studies (n=17,648) provided data for mode of transmission. The most common mode of transmission was travel related (58.1%, 95% CI 51.1-64.8), followed by close contacts (43.1%, 95% CI 37.2-49.2), and finally community spread (27.4%, 95% CI 18.4-38.7).

The pooled mean time from illness onset to first hospitalization was 5.5 days (95% CI 4.6-6.4) (26 studies, 3,508 patients, Table 1 ). This duration was shorter in studies outside Mainland China (3.3 days, 95% CI 2.2-4.5) compared to within Mainland China (5.7 days, 95% CI 4.8-6.7) (Supplemental Table 2A ) (p=0.002).

Within Mainland China, the time from illness onset to hospitalization was longer in Hubei province (7.5 days, 95% CI 5.7-9.2) compared with outside Hubei province (4.5 days, 95% CI 3.8-5.3) (p=0.003) (Supplemental Table 2B ).

The most common symptom was fever (78.8%, 95% CI 76.2-81.3), followed by cough (53.9%, 95% CI 50.0-57.7) and malaise 37.9% (95% CI 29.5-47.1). In contrast to other respiratory viral infections, the proportion of individuals with rhinorrhea was low (7.5%, 95% CI 5.7-9.6). With regards to gastrointestinal symptoms, the proportion of individuals with diarrhea was 9.5% (95% CI 7.8-11.5), while abdominal pain and vomiting was less common (4.5%, 95% CI 3.3-6.2 and 4.7%, 95% CI 3.8-5.8, respectively). mechanical ventilation than outside these areas (about 11% vs. 5%). Together, these data suggest the presence of delayed diagnosis and care leading to more severe disease at presentation likely due to the overwhelmed healthcare resources at the onset of this pandemic, which advocates for local preparedness to prevent severe disease progression and mortality.

With regards to presenting symptoms as potential predictors for disease progression, abdominal pain, an infrequent symptom, was notably strongly associated with severe COVID-19 disease. Those who present with abdominal pain should be more closely monitored for rapid decompensation. Similarly, patients withlow lymphocyte and albumin levels may have a more severe course of disease. We hypothesize that people at most risk for dying may be the ones that are malnourished, as reflected in low albumin. This hypothesis is probable especially when we look at countries such as the USA where clusters of COVID-19 cases appearing in elderly nursing homes carry a disproportionate number of deaths [15] . Therefore, this is an area that needs further research especially as the world's population continues to age [16] and as the pandemic marches to resource limited regions where malnutrition may be more common.

This article is protected by copyright. All rights reserved.

Among children, the mortality was nearly 4%, with 8% requiring ICU admission and 6% requiring mechanical ventilation. This pooled data may be limited by the small numbers of included patients, and we note that only 1.8% of patients in a recent study were admitted to the ICU [17] . Similarly, the pooled data shows that among pregnant individuals, 7% were admitted to the ICU, fetal loss occurred in 5%, and half develop obstetric related complications. However, our pooled data were based on only 43 patients drawn from 6 studies and should be interpreted with caution, but these findings warrant further investigation.

Our study is not without its limitations. Due to the lack of age group studies, we were unable to perform any sub-analyses by age groups other than the pediatric population. As the proportion of individuals with mild or asymptomatic COVID-19 infection may be much higher than expected, the pooled data we report is likely to be an over-estimate as most of the data comes from hospital-based studies. With the pandemic constantly evolving, a recent study was published after our study completion showing a 21% mortality in New York City [18] . Another limitation of our study is the fact that we included case reports to avoid missing potentially important data for this new pandemic, but case report data may bias towards the extremes or atypical. However, we performed sensitivity analyses that excluded studies with less than 10 patients and found similar results. Part of the differences in death rates among the different studies This article is protected by copyright. All rights reserved.

and countries/regions could also be attributed to how COVID-19 deaths are reported. Some countries may only be reporting deaths that are felt to be a direct cause of COVID-19 and not just deaths occurring in COVID-19 patients.

Therefore, a universal definition of which deaths should be reported needs to be developed. Nonetheless, these data are important for each respective country to determine their death rate in comparison to others when developing their own policies addressing COVID-19. In addition, the majority of studies included in our meta-analysis are hospital-based and/or tertiary care center-based studies, so our data may not be generalizable to affected patients outside of this setting, and further studies focusing on less severe community patients are needed. Lastly, as the pandemic spreads across the globe, additional data have become available for other regions not well represented in this study; therefore, more updated review and meta-analysis providing data for more regions of the world are needed.

In conclusion, we provide a large systemic review and regarding the clinical features and associations with severe COVID-19 disease. These data can inform healthcare providers and policy decision makers as to how best to identify and monitor patients at most risk for the development of severe COVID-19 as well as to identify vulnerable populations where special measures to prevent COVID-19 transmission may be needed. 

An Official Clinical Practice Guideline of the

Clinical management of severe acute respiratory infection when COVID-19 disease is suspected: interim guidance

Introduction to Meta-Analysis

Nursing Homes Are Ground Zero for COVID-19 Pandemic

SARS-CoV-2 Infection in Children

This article is protected by copyright. All rights reserved.